INTRODUCTION {#S0001}
============

Few studies have assessed the usefulness of NIV in patients with severe CAP. Nevertheless, predictors of NIV failure have been reported in different studies ([@CIT0001]--[@CIT0005]). Recently, Carrillo et al. noted these risk factors for NIV failure: radiographic worsening infiltration 24 hours after admission, maximum sepsis-related organ failure assessment (SOFA) score at admission and after 1 hour of NIV, higher heart rate, lower PaO~2~/FIO~2~ and bicarbonate ([@CIT0002]).

The debate concerning the use of NIV for treatment of severe CAP increased during H1N1 pandemic. Initially, NIV was felt to be contraindicated because of a hypothetical risk of spreading the infection. This hypothesis was refuted by Simmonds et.al. who found that the droplets generated during NIV are \> 10 µm; these are unlikely to be airborne ([@CIT0006]).

Over time, NIV success increased ([@CIT0007], [@CIT0008]). The success rate was as high as 76% with avoidance of intubation and fewer associated infection complications (e.g., sepsis, septic shock and/or catheter-related infections ([@CIT0006]). However, despite good outcomes in H1N1 patients and more recent randomized studies on the use of helmet continuous positive airway pressure (CPAP) versus oxygen therapy in severe hypoxemic respiratory failure due to pneumonia, in which the technique reduced the intubation rate ([@CIT0009], [@CIT0010]), the efficacy of NIV in pneumonia has not been definitively established ([@CIT0011]). Predictors of NIV failure have not been well defined ([@CIT0012]). From our long experience with NIV, we learned that appropriate patient selection is the key to success ([@CIT0013]).

The aim of this study was to evaluate the efficacy of NIV and factors related to its failure and mortality in patients with CAP and severe acute respiratory failure (ARF).

MATERIALS AND METHODS {#S0002}
=====================

We retrospectively followed 130 consecutive patients with severe ARF due to CAP defined as the ratio of arterial oxygen tension to inspired oxygen fraction (PaO~2~/FIO~2~) \<250 receiving NIV treatment in the RMU of Sestri Levante Hospital, from June 2005 to July 2014. The RMU has four non-invasive monitored beds and admits patients with severe respiratory failure who need non-invasive ventilation. The RMU has both ventilators specifically designed for NIV and invasive ventilation (IMV). Our units can switch to invasive measures e.g., intubation and intensive care unit (ICU) admission quickly.

This study received the approval of Ethics Committee of ASL4 Chiavarese, Italy (n°302) and was carried out in accordance with the Helsinki Declaration. All the patients gave informed consent for NIV treatment and for the study.

Pneumonia was defined as a new pulmonary infiltrate on the admission chest radiograph with symptoms and signs of lower respiratory tract infection according to the American Thoracic Society and Infectious Disease Society of America (IDSA/ATS) guidelines ([@CIT0002], [@CIT0007]).

Patients' degree of disease severity and organ failure were estimated using Simplified Acute Physiology Score (SAPS)-II and Confusion, Elevated Blood Urea Nitrogen, Respiratory Rate and Blood pressure plus Age ≥65 years (CURB65) score ([@CIT0002]). The exclusion criteria were any degree of immunosuppression, lack of spontaneous breathing, gasping, anatomical evidence of functional airway obstruction and gastrointestinal bleeding, or ileus, massive agitation, severe hypoxemia or acidosis (pH \< 7.10) ([@CIT0002], [@CIT0014], [@CIT0015]). Upon admission, all patients received empirical antimicrobial therapy according to the IDSA/ATS guidelines ([@CIT0016]).

Upon admission, specific urinary tests for Streptococcus pneumonia and Legionella pneumophila as well as blood culture were performed for all patients.

The indication for NIV use followed an established protocol: moderate to severe dyspnea accompanied by respiratory rate ≥ 30 breaths/m, signs of respiratory distress (e.g. use of accessory respiratory muscles), (PaO~2~/FiO~2~) \< 250 ([@CIT0002], [@CIT0013]--[@CIT0015]).

The inability of patient to adapt himself/herself to the device or unwillingness to undergo NIV was considered a contraindication for NIV.

Patients were ventilated using pressure support ventilation (PSV) or bi-level-ST ventilation (BIPAP).

The following parameters were recorded upon admission: age, sex, co-morbidities, number of lobes involved on chest x-ray or on chest computed tomography (CT), Opravil radiological score ([@CIT0017]), PaO~2~ on room air, PaCO~2~, pH, PaO~2~/FIO~2~ ratio, alveolar-arterial gradient (A-aDO~2~), Simplified Acute Physiology Score (SAPS) II, Kelly-Matthay scale, ventilation mode, setting of mechanical ventilator and PaO~2~/FIO~2~ after 1 hour of non-invasive ventilation. If a patient who underwent NIV did not experience an improvement of PaO~2~/FIO~2~ ratio of more than 175 after 1 hour of continued NIV, and/or if one or more complications occurred (neurological impairment, persistence of dyspnea and tachypnea, hemodynamic instability and intolerance of the interface, the patient was considered to have failed NIV and IMV was initiated. EPAP or PEEP (positive end expiratory pressure) was set initially at 5 cm H2O and the level was raised by 1-2 cm H2O if needed to achieve PaO~2~ \> 60 mmHg or SpO~2~ of \> 90%. Inspiratory pressure ventilation was increased, starting from 10 cmH2O, in increments of 2-3 cmH2O to obtain a tidal volume (VT) of 6-8 ml/Kg and a respiratory rate \< 30 breaths/m'. Conversely, NIV was deemed successful when respiratory failure improved and the patient did not feel the need for more than 48 hours of ventilator treatment having a PaO~2~/FiO~2~ ratio \> 250 with spontaneous breathing ([@CIT0003], [@CIT0013]).

Primary outcomes {#S20003}
----------------

NIV failure and hospital mortality were the primary outcomes.

Secondary outcomes {#S20004}
------------------

Changes in arterial blood gases (ABG) analysis at admission and after 1 hour of NIV, NIV duration and the length of hospital stay were the secondary outcomes.

Statistical analysis {#S20005}
--------------------

Continuous variables expressed as mean ± standard deviation were compared with the regression analysis corrected for age. Categorical variables expressed as number and percentages were compared using chi-square test. A P-value ≤0.05 was considered significant. The predictors identified as predictors of NIV failure and hospital mortality were analyzed initially with univariate regression analysis and therefore, were also included in a multivariate logistic regression analysis. Adjusted odds ratios (OR) and 95% confidence interval (CI) were computed for variables independently associated with NIV failure or hospital mortality. The predictive capacity for NIV failure or hospital mortality of quantitative variables was assessed with receiver-operating characteristic (ROC) curves; the area under the curve (AUC), optimal cut-off values, sensitivity, specificity and positive and negative predictive values were calculated. Data analysis was made with statistical software R-Project version 2.13.2.

RESULTS {#S0006}
=======

One hundred and thirty patients admitted with CAP received NIV (76 males and 54 females aged 59.74±16.17 years) for 90±96 hours, i.e., 3.7±3.3 days (mean ± SD). During NIV treatment, the pressure support ventilation (PSV) was 11±5 cm H2O and PEEP was 8±4 cmH2O. NIV was successfully used in 104 patients (80.0 %). Twenty-six patients experienced NIV failure; 18 were intubated and admitted to ICU. Eight other patients had previously stated that they did not want to be intubated and died. The main reasons for intubation were worsening of respiratory insufficiency (10 patients), cardio-respiratory arrest (four patients), and multi-organ failure (four patients).

Eight patients who were not intubated died because of multi-organ failure (three patients) and worsening of respiratory failure (five patients).

Acute respiratory failure de novo {#S20007}
---------------------------------

Acute respiratory failure *de novo* was considered as a separate entity ([@CIT0002]) in which CAP occurred in patients with no previous cardio-respiratory co-morbidities. Patients in the *de novo* group who failed NIV had more severe scores (CURB 65 and SAPS II), more extensive radiological findings (Opravil score), and more severe respiratory impairment at admission (lower PaO~2~/FiO~2~ ratio and higher A-aDO~2~). They also presented with worse oxygenation and gas exchange, along with a higher respiratory rate after 1 h of NIV and after 24 hours. Moreover, at admission they presented with higher values of LDH and C-reactive protein. Patients who demonstrated NIV success had a SAPS II ≤ 34 and PaO~2~/FiO~2~ after 1 hour of NIV \> 175, previously indicated marker of NIV success (P ≤ 0.001) ([@CIT0004]) as well as lower A-aDO~2~ after 1 hour of NIV and after 24 hours.

Patients with previous cardiac or respiratory disease were older and had higher PaCO~2~ and bicarbonate, lower arterial pH and decreased consciousness at admission. But the only significant difference with the *de novo* respiratory failure group was in age (73.±15 versus 47±16 years, P ≤ 0.001) ([Table 1](#T0001){ref-type="table"}).

###### 

Clinical and ventilatory characteristics of the two groups

                                                            De novo ARF 56 pts   Previous CR ARF 74 pts   P-value            
  --------------------------------------------------------- -------------------- ------------------------ --------- -------- -----------
  **age**                                                   47                   *16*                     73        *15*     *\<0,001*
  **Male**                                                  38                                            41                 *0.33*
  **Female**                                                18                                            33        *15,5*   *0.21*
  **SAPS II**                                               21                   *10*                     33        *11*     0.31
  **Lobes (number)**                                        3                    *1*                      3         *1*      0.93
  **Chest X ray score[\*](#TF0001){ref-type="table-fn"}**   8                    *3*                      8         *3*      0.99
  **RMU STAY (hours)**                                      162                  *119*                    116       *136*    0.74
  **CURB65**                                                1                    *1*                      2         *1*      0.33
  **HCO** ~**3**~                                           23                   *1*                      27        *7*      0.33
  **C-R Prot**                                              22                   *9*                      22        *9*      0,25
  **LDH**                                                   439                  *211*                    576       *522*    0.07
  **Respiratory rate**                                      32                   *4*                      32        *7*      0.14
  **Heart rate**                                            103                  *11*                     105       *14*     0.67
  **PaO** ~**2**~                                           48,50                *12*                     55        *15*     0.13
  **PaCO** ~**2**~                                          44                   *27*                     60        *40*     0.47
  **pH**                                                    7,40                 *0,10*                   7,35      *0,11*   0,27
  **PaO** ~**2**~ **/FiO** ~**2**~                          162                  *48*                     162       *45*     0.99
  **A-aDO** ~**2**~                                         121                  *92*                     127       *102*    0.80
  **KMS**                                                   1                    *1*                      2         *1*      0.12

ARF Acute respiratory failure; CR cardiac-respiratory disease

Opravil chest X-ray score

SAPS II = Simplified acute physiology score; CURB 65 = confusion, elevated blood urea,respiratory rate,blood pressure plus age ≥ 65 years; A-aDO~2~ = Alveolar-arteriolar gradient; RMU STAY =Length of stay in High-dependency Respiratory Unit; KMS = Kelly-Matthay Scale

Patients in the ARF group did not have significant differences at admission and showed only a drop in respiratory rate and heart rate after 1 hour of NIV in patients with NIV success. In those who failed NIV there was a significant increase of A-aDO~2~ after 24 hours in patients (P ≤ 0.02) ([Table 2](#T0002){ref-type="table"}). In multivariate analysis of predictors associated with NIV failure in the two groups, a higher heart rate after 1 hour, a higher A-aDO~2~ after 24 hours, and a higher X-ray score Opravil score) at admission predicted failure ([Table 3](#T0003){ref-type="table"}).

###### 

Variables associated with failure of non-invasive ventilation in the two groups

                                     « De novo »ARF   Previous cardiac or respiratory ARF                                                                                   
  ---------------------------------- ---------------- ------------------------------------- -------- ------- -------- --------- ------- -------- ------- -------- --------- ------------------------------------
  **A-aDO** ~**2**~                  0                99,83                                 78,33    238,2   52,21    \<0,001   130,6   114,49   73,25   50,01    0,33      
                                     1                162,9                                 57,38    269,6   199,66   0,03      124,7   96,45    114,5   90,25    0,8       
                                     2                21,35                                 23,85    170     90,83    \<0,001   70,61   117,9    213,3   68,37    0,02      [\*](#TF0002){ref-type="table-fn"}
  **CURB65**                         0                1,22                                  0,52     1,8     0,45     0,03      2,21    1,19     2,5     0,58     0,64      
  **Heart rate**                     0                103,1                                 10,2     108     4        0,3       104,6   13,31    110,8   13,1     0,4       
                                     1                92,48                                 8,03     111,8   11,23    \<0,001   95,82   9,54     109,8   13,33    0,01      [\*](#TF0002){ref-type="table-fn"}
                                     2                82,39                                 8,98     120,8   5,93     \<0,001   87,06   13,56    116     19,11    \<0,001   [\*](#TF0002){ref-type="table-fn"}
  **C-R prot.**                      0                19,65                                 8,1      37,8    5,22     \<0,001   20,18   8,06     22      6,48     0,67      
  **LDH**                            0                343,9                                 111,86   819,4   149,14   \<0,001   518,9   505,17   841,3   295,7    0,22      
  **PaO** ~**2**~ **/FiO** ~**2**~   0                182,1                                 49,38    117,4   14,72    0,008     170     43,25    170,8   43,37    0,9       
                                     1                199,7                                 43,34    121,4   45,99    0,001     220,9   62,68    217,5   69,23    0,92      
                                     2                376,9                                 62,85    176     122,19   \<0,001   283,9   80,12    193     145,82   0,06      
  **PaCO** ~**2**~                   0                43,09                                 23,59    48,8    18,14    0,6       61,61   45,27    46,75   17,8     0,5       
                                     1                40,0                                  15,29    40,8    9,52     0,92      51,73   25,95    49      21,32    0,82      
                                     2                38,83                                 7,3      45      15,57    0,2       45,91   14,49    60,5    26,56    0,09      
  **pH**                             0                7,4                                   0,11     7,37    0,08     0,6       7,33    0,17     7,4     0,09     0,5       
                                     1                7,41                                  0,07     7,42    0,08     0,8       7,35    0,11     7,4     0,11     0,4       
                                     2                7,4                                   0,03     7,42    0,1      0,3       7,38    0,08     7,35    0,13     0,6       
  **Resp. rate**                     0                31,78                                 3,29     34      3,74     0,2       32,85   7,14     35,5    5,26     0,5       
                                     1                25,17                                 2,66     33,2    3,7      \<0,001   27      4,03     34,5    4,12     0,001     [\*](#TF0002){ref-type="table-fn"}
                                     2                20,87                                 4.24     31,4    3,85     \<0,001   20,09   2,2      33,7    5,91     \<0,001   [\*](#TF0002){ref-type="table-fn"}
  **SAPS II**                        0                19,13                                 8,68     32      9,38     0,006     34,12   12,07    29,75   14,57    0,5       
  **Chest X ray score**              0                8                                     2,32     10,6    1,34     0,02      7,24    2,33     10      3,16     0,04      [\*](#TF0002){ref-type="table-fn"}

0  At admission       SAPS II = Simplified acute physiology score

1  After 1 hour of NIV    CURB 65 = confusion, elevated blood urea, respiratory rate, blood pressure plus age ≥ 65 years

2  After 24 hours of NIV   A-aDO~2~ = Alveolar-arteriolar gradient

               RMU STAY =Length of stay in Respiratory Monitoring Unit

               C-R prot. = C reactive protein

Variable entered into a multivariate logistic regression analysis

###### 

Multivariate analysis of variables independently associated with non invasive ventilation failure in the total population

  Variables           T   Label      Adj.OR   95% CI   P-value   AUC       Optimal cut-off   Sensitivity (%)   Specificity (%)   Likelihood ratio   Predictive value                 
  ------------------- --- ---------- -------- -------- --------- --------- ----------------- ----------------- ----------------- ------------------ ------------------ ------ ------ ------
  **A-aDO** ~**2**~   2   NIV fail   214      19.4     12051     \<0.001   0.885             131               88.90             92.90              12.44              0.12   66.7   98.1
  **heart_rate**      1   NIV fail   12.75    2.6      69.4      0.002     0.862             108               55.60             91.11              6.22               0.49   50.0   92.7
  **X-ray score**     0   NIV fail   14.13    2.5      92.1      0.003     0.821             11                44.40             96.40              8.30               0.59   57.1   91.4

NIV fail = Non invasive ventilation failure

A-aDO~2~= Alveolar-arteriolar gradient

X-ray score= Chest X ray score (Opravil)

      T 0 at admission

      T1 after 1hour of NIV

      T2 after 24 hours of NIV

      Adj OR = Adjusted odds ratio

      CI = confidence interval

      AUC = area under the curve

Survival {#S20008}
--------

Hospital survivors had less pulmonary involvement as assessed by X ray (Opravil) score, a lower LDH at admission, a greater improvement of respiratory and heart rate after 24 hours of NIV and a better PaO~2~/FiO~2~ and A-aDO~2~ after 24 hours compared with those who died.

In patients with *de novo* ARF survival was also related to A-aDO~2~ at admission and after 1 hour of NIV as well as initial C-reactive protein. In patients with previous cardiac and respiratory disease, ARF survival was also associated with a lower severity score at admission (CURB 65 and SAPS II), lower PaCO~2~ and higher pH after 24 hours of NIV along with a lower respiratory rate after 1 hour of NIV. There was no significant difference between NIV duration or length of stay in the RMU among patients with NIV success or NIV failure ([Table 4](#T0004){ref-type="table"}). In total population, the multivariate analysis identified a higher LDH at admission, a higher X-ray score (Opravil) at admission, higher heart rate after 24 hours and higher A-aDO~2~ after 24 hours as independent predictors of hospitality mortality ([Table 5](#T0005){ref-type="table"}). [Figure 1](#F0001){ref-type="fig"} shows the predictors of hospital mortality using ROC curves.

![Performance predictive of mortality of the scores evaluated using ROC curves.](Tanaffos-13-020-g001){#F0001}

###### 

Variables associated with hospital mortality in the two groups

                                     « De novo »ARF   Previous cardiac or respiratory ARF                                                                            
  ---------------------------------- ---------------- ------------------------------------- ------- ------- ------- ------- ------- ------- -------- ------- ------- ------------------------------------
  **A-aDO** ~**2**~                  0                114,4                                 85,0    256,5   79,9    0.03    106,5   76,1    189,4    182,6   0.06    
                                     1                170,7                                 58,9    327,5   382,5   0.03    122,1   65,2    129,1    170,4   0.9     
                                     2                37,0                                  60,2    190,0   48,1    0.002   53,4    69,9    204,1    189,9   0.001   [\*](#TF0003){ref-type="table-fn"}
  **CURB65**                         0                1,3                                   0,5     2,0     0,0     0.07    2,0     1,1     3,0      0,8     0.03    
  **Heart rate**                     0                104,0                                 9,9     104,0   0,0     1       103,9   12,4    110,4    15,8    0.2     
                                     1                95,7                                  11,7    99,5    0,7     0.6     95,2    9,3     105,0    12,7    0.02    
                                     2                87,2                                  16,0    116,0   5,7     0.02    84,2    10,8    112,0    16,3    0.001   [\*](#TF0003){ref-type="table-fn"}
  **C-R Prot**                       0                21,8                                  9,9     37,0    4,2     0.04    20,4    8,1     20,4     7,6     0.9     
  **LDH**                            0                389,0                                 168,7   946,5   62,9    0.001   396,4   177,9   1124,1   810,0   0.001   [\*](#TF0003){ref-type="table-fn"}
  **PaO** ~**2**~ **/FiO** ~**2**~   0                174,5                                 51,5    120,0   0,0     0.2     170,3   43,4    169,3    42,9    0.9     
                                     1                190,0                                 49,4    130,0   84,9    0.1     225,9   60,2    201,0    70,4    0.3     
                                     2                356,1                                 94,6    145,0   77,8    0.005   300,7   68,3    177,9    102,6   0.001   [\*](#TF0003){ref-type="table-fn"}
  **PaCO~2~**                        0                43,2                                  22,4    55,5    30,4    0.5     57,9    41,5    67,8     51,3    0.6     
                                     1                39,8                                  14,6    44,5    12,0    0.7     49,7    26,4    57,6     21,0    0.4     
                                     2                38,8                                  7,4     54,5    21,9    0.02    43,8    10,8    61,0     25,3    0.006   
  **pH**                             0                7,4                                   0,1     7,3     0,1     0.4     7,4     0,1     7,3      0,3     0.2     
                                     1                7,41                                  0,07    7,44    0,1     0.6     7,37    0,1     7,31     0,1     0.1     
                                     2                7,40                                  0,04    7,38    0,1     0.4     7,39    0,0     7,30     0,1     0.004   
  **Resp. rate**                     0                32,2                                  3,4     32,0    5,7     0.9     32,0    7,0     37,3     5,0     0.06    
                                     1                26,3                                  4,2     30,0    2,8     0.2     26,4    3,7     32,9     4,1     0.001   
                                     2                22,0                                  5,2     33,0    1,4     0.006   20,3    3,7     26,1     6,8     0.002   [\*](#TF0003){ref-type="table-fn"}
  **SAPS II**                        0                20,8                                  9,7     30,0    14,1    0.2     30,8    9,0     44,1     16,9    0.004   
  **Chest X-ray score**              0                8,3                                   2,3     11,0    1,4     0.1     6,9     2,3     9,9      2,2     0.002   

0 At admission   SAPS II = Simplified acute physiology score

1 After 1 h NIV   CURB 65 = confusion, elevated blood urea, respiratory rate, blood pressure plus age ≥ 65 years

2 After 24 h NIV   A-aDO~2~ = Alveolar-arteriolar gradient

            RMU STAY =Length of stay in Respiratory Monitoring Unit

            C-R prot = C reactive protein

Variable entered into a multivariate logistic regression analysis

DISCUSSION {#S0009}
==========

Patients with severe respiratory failure due to CAP and previous cardiac or respiratory disease usually have a better response to NIV than patients with *de novo* acute respiratory failure (as demonstrated in previous studies) ([@CIT0002], [@CIT0018], [@CIT0019]). Few studies have investigated the benefits of NIV in patients with severe CAP: the oldest showed good results principally in patients with chronic obstructive pulmonary disease (COPD) and hypercapnic respiratory failure ([@CIT0018]). Subsequent researches demonstrated that NIV was effective in decreasing the rates of intubation and mortality compared with high concentration oxygen therapy ([@CIT0009], [@CIT0010], [@CIT0020]). Another recent investigation examined patients with ARF *de novo* and ARF due to cardiac or respiratory disease; this study showed that NIV is a safe and effective modality. In patients with ARF *de novo*, NIV failure was associated with a high mortality ([@CIT0002]).

Three recent studies ([@CIT0021]--[@CIT0023]) support the effectiveness of NIV in severe CAP. The first evaluated 151 COPD patients requiring ICU admission, who underwent NIV and reported a failure rate of 31.1%. Nearly 70% of patients has success with NIV. Non-invasive ventilation, hypertension and corticosteroid treatment were associated with decreased mortality; whereas bilateral infiltration, length of ICU stay and duration of IMV were associated with increased mortality ([@CIT0021]). The second study included a cohort of 1,946 elderly immunocompromised patients. Unexpectedly, patients who underwent NIV had decreased mortality at 90 days when compared to those treated with invasive mechanical ventilation. The authors concluded that data obtained suggest that physicians should consider the use of NIV for the elderly immunocompromised patients hospitalized with pneumonia. It seemed that patients receiving NIV fared no worse than similar patients receiving IMV ([@CIT0022]). The third study reported a similar NIV success rate (75%) related to early use of NIV and to strict patient selection protocol ([@CIT0023]).

Only a few studies evaluated the interrelations of radiographic findings and the need for mechanical ventilation in patients admitted with pneumonia ([@CIT0024], [@CIT0025]). Erdem et al. demonstrated that patients with bilateral pulmonary involvement most often needed NIV while those with multi-lobar involvement more frequently required IMV ([@CIT0025]). A final consideration concerning a high rate of NIV success (80%): the success begins in the emergency department where a strict selection protocol is followed. For example, a patient with PaO~2~/FIO~2~ratio \< 150 was not considered for NIV ([@CIT0013], [@CIT0026]). Our center has strict and continuous monitoring at admission and during the stay at the RMU. Another point worth considering is our long use of NIV. Success could be the result of the expertise of our team (physicians and nurses) who have been using NIV for more than 10 years ([@CIT0027]).

We are aware that this real-life study has important limitations: 1. It is a single center study and reflects the skills of a single group. Therefore, these data may not be generalized to other settings ([@CIT0028]). 2. The effectiveness of any treatment is established by a randomized controlled trial. In the absence of a control group, definitive conclusions cannot be drawn. 3. Microbiological data were available only for a minority of our patients; therefore, different pathogens may have affected patient outcomes. 4. The criteria for intubation were not standardized "a priori" but followed our institutional guidelines. This reflects the "real life"scenario of the study.

###### 

Multivariate analysis of variables independently associated with hospital mortality in the total population

  Variables         T   Label    Adj OR   95% CI           P value   AUC     Optimal cutoff   Sensitivity (%)   Specificity (%)   Likelihood ratio   Predictive value          
  ----------------- --- -------- -------- -------- ------- --------- ------- ---------------- ----------------- ----------------- ------------------ ------------------ ------ ------
  **A-aDO~2~**      2   H mort   1107.1   7.1      880.0   0.03      0.902   247              30.00             98.20             16.50              0.71               75.0   88.5
  **Heart rate**    2   H mort   6815.2   42.0     770.0   0.03      0.908   108              80.00             92.70             11,00              0.22               66.7   96.2
  **LDH**           0   H mort   31.7     3.1      93.2    0.01      0.956   728              60.00             94.50             13.40              0.42               68.4   92.9
  **X ray score**   0   H mort   12.6     0.9      34.1    0.04      0.803   11               40.00             94.50             7.33               0.63               57.1   90.7

A-aDO~2~=Alveolar-arteriolar gradient    X-ray score= Chest X-ray (Opravil)

T0 at admission            T2 after 24 hours of non-invasive ventilation

Adj OR = Adjusted odds ratio      CI = Confidence interval

AUC = Area under the curve

CONCLUSIONS {#S0010}
===========

In conclusion, in this observational study, successful treatment was strongly related to less pulmonary involvement and to a prompt and continued response to medical and NIV treatment. Continuous and strict monitoring in an appropriate environment is of paramount importance.
